Multiple sclerosis: risk factors, prodromes, and potential causal pathways

The Lancet Neurology

Volumn 9, Issue 7, 2010, Pages 727-739

  Ramagopalan, Sreeram V ^a,b   Dobson, Ruth ^a   Meier, Ute C ^a   Giovannoni, Gavin ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN D;

BIRTH; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; ETHNICITY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LATITUDE; MULTIPLE SCLEROSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX RATIO; SMOKING; VITAMIN SUPPLEMENTATION;

DISEASE SUSCEPTIBILITY; ENVIRONMENT; ENVIRONMENTAL EXPOSURE; HUMANS; MULTIPLE SCLEROSIS; RISK FACTORS; SEX FACTORS;

EID: 77953394241     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(10)70094-6     Document Type: Review

References (150)

1. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshenker B.G. Multiple sclerosis. N Engl J Med 343 (2000) 938-952
2. Giovannoni G., and Ebers G. Multiple sclerosis: the environment and causation. Curr Opin Neurol 20 (2007) 261-268
3. White T., Anjum A., and Schulz S.C. The schizophrenia prodrome. Am J Psychiatry 163 (2006) 376-380
4. Paty D.W., and Ebers G.C. Multiple sclerosis (1998), F A Davis Company, Philadelphia
5. Miller D., Barkhof F., Montalban X., Thompson A., and Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 4 (2005) 281-288
6. Okuda D.T., Mowry E.M., Beheshtian A., et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 72 (2009) 800-805
7. Flint J., and Munafo M.R. The endophenotype concept in psychiatric genetics. Psychol Med 37 (2007) 163-180
8. Dyment D.A., Ebers G.C., and Sadovnick A.D. Genetics of multiple sclerosis. Lancet Neurol 3 (2004) 104-110
9. Robertson N.P., Fraser M., Deans J., Clayton D., Walker N., and Compston D.A. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain 119 (1996) 449-455
10. Sadovnick A.D., Baird P.A., and Ward R.H. Multiple sclerosis: updated risks for relatives. Am J Med Genet 29 (1988) 533-541
11. Willer C.J., Dyment D.A., Risch N.J., Sadovnick A.D., and Ebers G.C. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci USA 100 (2003) 12877-12882
12. Ebers G.C., Sadovnick A.D., Dyment D.A., Yee I.M., Willer C.J., and Risch N. Parent-of-origin effect in multiple sclerosis: observations in half-siblings. Lancet 363 (2004) 1773-1774
13. Jersild C., Fog T., Hansen G.S., Thomsen M., Svejgaard A., and Dupont B. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 2 (1973) 1221-1225
14. Barcellos L.F., Oksenberg J.R., Begovich A.B., et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 72 (2003) 710-716
15. Marrosu M.G., Murru R., Murru M.R., et al. Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia. Hum Mol Genet 10 (2001) 2907-2916
16. Dyment D.A., Herrera B.M., Cader M.Z., et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet 14 (2005) 2019-2026
17. Masterman T., Ligers A., Olsson T., Andersson M., Olerup O., and Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 48 (2000) 211-219
18. Barcellos L.F., Sawcer S., Ramsay P.P., et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 15 (2006) 2813-2824
19. Ramagopalan S.V., Morris A.P., Dyment D.A., et al. The inheritance of resistance alleles in multiple sclerosis. PLoS Genet 3 (2007) e150
20. Dean G., Yeo T.W., Goris A., et al. HLA-DRB1 and multiple sclerosis in Malta. Neurology 70 (2008) 101-105
21. Lincoln M.R., Ramagopalan S.V., Chao M.J., et al. Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility. Proc Natl Acad Sci USA 106 (2009) 7542-7547
22. De Jager P.L., Jia X., Wang J., et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 41 (2009) 776-782
23. Hafler D.A., Compston A., Sawcer S., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357 (2007) 851-862
24. Kurtzke J.F., Beebe G.W., and Norman Jr. J.E. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology 29 (1979) 1228-1235
25. Herrera B.M., Ramagopalan S.V., Lincoln M.R., et al. Parent-of-origin effects in MS. Observations from avuncular pairs. Neurology 71 (2008) 799-803
26. Hoppenbrouwers I.A., Liu F., Aulchenko Y.S., et al. Maternal transmission of multiple sclerosis in a Dutch population. Arch Neurol 65 (2008) 345-348
27. Ramagopalan S.V., Yee I.M., Dyment D.A., et al. Parent-of-origin effect in multiple sclerosis. Observations from interracial matings. Neurology 73 (2009) 602-605
28. Handel AE, Ebers GC, Ramagopalan SV. Epigenetics: molecular mechanisms and implications for disease. Trends Mol Med; 16: 7-16.
29. Chao M.J., Ramagopalan S.V., Herrera B.M., et al. Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex. Hum Mol Genet 18 (2009) 261-266
30. Orton S.M., Herrera B.M., Yee I.M., et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 5 (2006) 932-936
31. Wallin M.T., Page W.F., and Kurtzke J.F. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann Neurol 55 (2004) 65-71
32. Hirst C., Ingram G., Pickersgill T., Swingler R., Compston D.A., and Robertson N.P. Increasing prevalence and incidence of multiple sclerosis in South East Wales. J Neurol Neurosurg Psychiatry 80 (2009) 386-391
33. Alonso A., and Hernan M.A. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71 (2008) 129-135
34. Whitacre C.C. Sex differences in autoimmune disease. Nat Immunol 2 (2001) 777-780
35. Ascherio A., and Munger K.L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 61 (2007) 288-299
36. Thacker E.L., Mirzaei F., and Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 59 (2006) 499-503
37. Sundstrom P., Juto P., Wadell G., et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 62 (2004) 2277-2282
38. Levin L.I., Munger K.L., Rubertone M.V., et al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293 (2005) 2496-2500
39. Nielsen T.R., Rostgaard K., Nielsen N.M., et al. Multiple sclerosis after infectious mononucleosis. Arch Neurol 64 (2007) 72-75
40. Ramagopalan S.V., Valdar W., Dyment D.A., et al. Association of infectious mononucleosis with multiple sclerosis. A population-based study. Neuroepidemiology 32 (2009) 257-262
41. Banwell B., Krupp L., Kennedy J., et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 6 (2007) 773-781
42. Yeh E.A., Chitnis T., Krupp L., et al. Pediatric multiple sclerosis. Nat Rev Neurol 5 (2009) 621-631
43. Pohl D., Krone B., Rostasy K., et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 67 (2006) 2063-2065
44. Hawkes C.H. Smoking is a risk factor for multiple sclerosis: a metanalysis [sic]. Mult Scler 13 (2007) 610-615
45. Hernan M.A., Olek M.J., and Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol 154 (2001) 69-74
46. Hedstrom A.K., Baarnhielm M., Olsson T., and Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 73 (2009) 696-701
47. Kurtzke J.F. Geographic distribution of multiple sclerosis: an update with special reference to Europe and the Mediterranean region. Acta Neurol Scand 62 (1980) 65-80
48. Hammond S.R., McLeod J.G., Millingen K.S., et al. The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart. Brain 111 (1988) 1-25
49. Kampman M.T., and Brustad M. Vitamin D: a candidate for the environmental effect in multiple sclerosis-observations from Norway. Neuroepidemiology 30 (2008) 140-146
50. Weinstock-Guttman B., Jacobs L.D., Brownscheidle C.M., et al. Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. Mult Scler 9 (2003) 293-298
51. Acheson E.D., Bachrach C.A., and Wright F.M. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatr Scand Suppl 35 (1960) 132-147
52. van der Mei I.A., Ponsonby A.L., Dwyer T., et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 327 (2003) 316
53. Munger K.L., Zhang S.M., O'Reilly E., et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 62 (2004) 60-65
54. Vieth R., Cole D.E., Hawker G.A., Trang H.M., and Rubin L.A. Wintertime vitamin D insufficiency is common in young Canadian women, and their vitamin D intake does not prevent it. Eur J Clin Nutr 55 (2001) 1091-1097
55. van Dam R.M., et al. Potentially modifiable determinants of vitamin D status in an older population in the Netherlands: the Hoorn Study. Am J Clin Nutr 85 (2007) 755-761
56. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., and Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296 (2006) 2832-2838
57. Ascherio A., Munger K.L., and Simon K.C. Vitamin D and multiple sclerosis. Lancet Neurol 9 (2010) 599-612
58. Holick M.F. Vitamin D deficiency. N Engl J Med 357 (2007) 266-281
59. Willer C.J., Dyment D.A., Sadovnick A.D., Rothwell P.M., Murray T.J., and Ebers G.C. Timing of birth and risk of multiple sclerosis: population based study. BMJ 330 (2005) 120
60. Sotgiu S., Pugliatti M., Sotgiu M.A., et al. Seasonal fluctuation of multiple sclerosis births in Sardinia. J Neurol 253 (2006) 38-44
61. Bayes H.K., Weir C.J., and O'Leary C. Timing of birth and risk of multiple sclerosis in the Scottish population. Eur Neurol 63 (2009) 36-40
62. Alter M., Halpern L., Kurland L.T., Bornstein B., Leibowitz U., and Silberstein J. Multiple sclerosis in Israel. Prevalence among immigrants and native inhabitants. Arch Neurol 7 (1962) 253-263
63. Alter M., Leibowitz U., and Speer J. Risk of multiple sclerosis related to age at immigration to Israel. Arch Neurol 15 (1966) 234-237
64. Dean G. Annual incidence, prevalence, and mortality of multiple sclerosis in white South-African-born and in white immigrants to South Africa. BMJ 2 (1967) 724-730
65. Alter M., Okihiro M., Rowley W., and Morris T. Multiple sclerosis among Orientals and Caucasians in Hawaii. Neurology 21 (1971) 122-130
66. Dean G., and Kurtzke J.F. On the risk of multiple sclerosis according to age at immigration to South Africa. BMJ 3 (1971) 725-729
67. Dean G., McLoughlin H., Brady R., Adelstein A.M., and Tallett-Williams J. Multiple sclerosis among immigrants in Greater London. BMJ 1 (1976) 861-864
68. Kurtzke J.F., Beebe G.W., and Norman Jr. J.E. Epidemiology of multiple sclerosis in US veterans: III. Migration and the risk of MS. Neurology 35 (1985) 672-678
69. Elian M., and Dean G. Multiple sclerosis among the United Kingdom-born children of immigrants from the West Indies. J Neurol Neurosurg Psychiatry 50 (1987) 327-332
70. Elian M., Nightingale S., and Dean G. Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa and the West Indies. J Neurol Neurosurg Psychiatry 53 (1990) 906-911
71. Dean G., and Elian M. Age at immigration to England of Asian and Caribbean immigrants and the risk of developing multiple sclerosis. J Neurol Neurosurg Psychiatry 63 (1997) 565-568
72. Kurtzke J.F., Delasnerie-Laupretre N., and Wallin M.T. Multiple sclerosis in North African migrants to France. Acta Neurol Scand 98 (1998) 302-309
73. Hammond S.R., English D.R., and McLeod J.G. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain 123 (2000) 968-974
74. Karni A., Kahana E., Zilber N., Abramsky O., Alter M., and Karussis D. The frequency of multiple sclerosis in Jewish and Arab populations in greater Jerusalem. Neuroepidemiology 22 (2003) 82-86
75. Cabre P., Signate A., Olindo S., et al. Role of return migration in the emergence of multiple sclerosis in the French West Indies. Brain 128 (2005) 2899-2910
76. Smestad C., Sandvik L., Holmoy T., Harbo H.F., and Celius E.G. Marked differences in prevalence of multiple sclerosis between ethnic groups in Oslo, Norway. J Neurol 255 (2008) 49-55
77. Gale C.R., and Martyn C.N. Migrant studies in multiple sclerosis. Prog Neurobiol 47 (1995) 425-448
78. Pugliatti M., Riise T., Sotgiu M.A., et al. Evidence of early childhood as the susceptibility period in multiple sclerosis: space-time cluster analysis in a Sardinian population. Am J Epidemiol 164 (2006) 326-333
79. Ramagopalan S.V., Valdar W., Criscuoli M., et al. Age of puberty and the risk of multiple sclerosis: a population based study. Eur J Neurol 16 (2009) 342-347
80. Munger K.L., Chitnis T., and Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology 73 (2009) 1543-1550
81. Freedman D.M., Dosemeci M., and Alavanja M.C. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates. Occup Environ Med 57 (2000) 418-421
82. Lyon-Caen O., Jouvent R., Hauser S., et al. Cognitive function in recent-onset demyelinating diseases. Arch Neurol 43 (1986) 1138-1141
83. Young A.C., Saunders J., and Ponsford J.R. Mental change as an early feature of multiple sclerosis. J Neurol Neurosurg Psychiatry 39 (1976) 1008-1013
84. Engell T. A clinical patho-anatomical study of clinically silent multiple sclerosis. Acta Neurol Scand 79 (1989) 428-430
85. Gilbert J.J., and Sadler M. Unsuspected multiple sclerosis. Arch Neurol 40 (1983) 533-536
86. Lebrun C., Bensa C., Debouverie M., et al. Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. J Neurol Neurosurg Psychiatry 79 (2008) 195-198
87. Barkhof F., Filippi M., Miller D.H., et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120 part 11 (1997) 2059-2069
88. Tintore M., Rovira A., Martinez M.J., et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol 21 (2000) 702-706
89. Fisniku L.K., Brex P.A., Altmann D.R., et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131 (2008) 808-817
90. Dalton C.M., Chard D.T., Davies G.R., et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 127 (2004) 1101-1107
91. Van Au Duong M., Audoin B., Le Fur Y., et al. Relationships between gray matter metabolic abnormalities and white matter inflammation in patients at the very early stage of MS: a MRSI study. J Neurol 254 (2007) 914-923
92. Fernando K.T., Tozer D.J., Miszkiel K.A., et al. Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. Brain 128 (2005) 2911-2925
93. Rovaris M., Judica E., Ceccarelli A., et al. A 3-year diffusion tensor MRI study of grey matter damage progression during the earliest clinical stage of MS. J Neurol 255 (2008) 1209-1214
94. Kasper L.H., and Shoemaker J. Multiple sclerosis immunology: the healthy immune system vs the MS immune system. Neurology 74 suppl 1 (2010) S2-S8
95. van Oosten B.W., Lai M., Hodgkinson S., et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 49 (1997) 351-357
96. Segal B.M., Constantinescu C.S., Raychaudhuri A., Kim L., Fidelus-Gort R., and Kasper L.H. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 7 (2008) 796-804
97. Viglietta V., Baecher-Allan C., Weiner H.L., and Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199 (2004) 971-979
98. high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 35 (2005) 3343-3352
99. reg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. J Clin Invest 118 (2008) 3411-3419
100. Tzartos J.S., Friese M.A., Craner M.J., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172 (2008) 146-155
101. Antel J.P., Rosenkoetter M., Reder A., Oger J.J., and Arnason B.G. Multiple sclerosis: relation of in vitro IgG secretion to T suppressor cell number and function. Neurology 34 (1984) 1155-1160
102. Jacobsen M., Cepok S., Quak E., et al. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 125 (2002) 538-550
103. Jilek S., Schluep M., Rossetti A.O., et al. CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis. Clin Immunol 123 (2007) 105-113
104. Jilek S., Schluep M., Meylan P., et al. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 131 (2008) 1712-1721
105. Hintzen R.Q., and Giovannoni G. CSF analysis in suspected MS: do bands aid?. Neurology 70 (2008) 1059-1060
106. Freedman M.S., Thompson E.J., Deisenhammer F., et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 62 (2005) 865-870
107. Nilsson P., Larsson E.M., Maly-Sundgren P., Perfekt R., and Sandberg-Wollheim M. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol 252 (2005) 396-402
108. Soderstrom M., Ya-Ping J., Hillert J., and Link H. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 50 (1998) 708-714
109. Tintore M., Rovira A., Rio J., et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. Neurology 70 (2008) 1079-1083
110. Benczur M., Petranyl G.G., Palffy G., et al. Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor. Clin Exp Immunol 39 (1980) 657-662
111. Uchida A., Maida E.M., Lenzhofer R., and Micksche M. Natural killer cell activity in patients with multiple sclerosis: interferon and plasmapheresis. Immunobiology 160 (1982) 392-402
112. Braakman E., van Tunen A., Meager A., and Lucas C.J. Natural cytotoxic activity in multiple sclerosis patients: defects in IL-2/interferon gamma-regulatory circuit. Clin Exp Immunol 66 (1986) 285-294
113. Vranes Z., Poljakovic Z., and Marusic M. Natural killer cell number and activity in multiple sclerosis. J Neurol Sci 94 (1989) 115-123
114. Kreuzfelder E., Shen G., Bittorf M., et al. Enumeration of T, B and natural killer peripheral blood cells of patients with multiple sclerosis and controls. Eur Neurol 32 (1992) 190-194
115. Munschauer F.E., Hartrich L.A., Stewart C.C., and Jacobs L. Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls. J Neuroimmunol 62 (1995) 177-181
116. Kastrukoff L.F., Morgan N.G., Zecchini D., et al. A role for natural killer cells in the immunopathogenesis of multiple sclerosis. J Neuroimmunol 86 (1998) 123-133
117. Takahashi K., Miyake S., Kondo T., et al. Natural killer type 2 bias in remission of multiple sclerosis. J Clin Invest 107 (2001) R23-R29
118. Kastrukoff L.F., Lau A., Wee R., Zecchini D., White R., and Paty D.W. Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity. J Neuroimmunol 145 (2003) 103-114
119. Takahashi K., Aranami T., Endoh M., Miyake S., and Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain 127 (2004) 1917-1927
120. Bielekova B., Catalfamo M., Reichert-Scrivner S., et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 103 (2006) 5941-5946
121. Rinaldi L., Gallo P., Calabrese M., et al. Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI-active patients. Brain 129 (2006) 1993-2007
122. Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 28 (2007) 121-126
123. low cells. Brain 131 (2008) 1701-1711
124. Polman C.H., O'Connor P.W., Havrdova E., et al., AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 (2006) 899-910
125. Coles A.J., Compston D.A., Selmaj K.W., et al., CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359 (2008) 1786-1801
126. Hauser S.L., Waubant E., Arnold D.L., et al., HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358 (2008) 676-688
127. Bielekova B., and Becker B.L. Monoclonal antibodies in MS: mechanisms of action. Neurology 74 suppl 1 (2010) S31-S40
128. McFarland H.F., and Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8 (2007) 913-919
129. Friese M.A., and Fugger L. Pathogenic CD8(+) T cells in multiple sclerosis. Ann Neurol 66 (2009) 132-141
130. Goodin D.S. The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS One 4 (2009) e4565
131. Ascherio A., and Munger K.L. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann Neurol 61 (2007) 504-513
132. Healy B.C., Ali E.N., Guttmann C.R., et al. Smoking and disease progression in multiple sclerosis. Arch Neurol 66 (2009) 858-864
133. Di Pauli F., Reindl M., Ehling R., et al. Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler 14 (2008) 1026-1030
134. Farrell R.A., Antony D., Wall G.R., et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 73 (2009) 32-38
135. Lunemann J.D., Tintore M., Messmer B., et al. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol 67 (2009) 159-169
136. Hasler G., Drevets W.C., Gould T.D., Gottesman I.I., and Manji H.K. Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry 60 (2006) 93-105
137. Somma P., Ristori G., Battistini L., et al. Characterization of CD8+ T cell repertoire in identical twins discordant and concordant for multiple sclerosis. J Leukoc Biol 81 (2007) 696-710
138. Nuwer M.R., Visscher B.R., Packwood J.W., and Namerow N.S. Evoked potential testing in relatives of multiple sclerosis patients. Ann Neurol 18 (1985) 30-34
139. De Stefano N., Cocco E., Lai M., et al. Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis. Ann Neurol 59 (2006) 634-639
140. Corvol J.C., Pelletier D., Henry R.G., et al. Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci USA 105 (2008) 11839-11844
141. De Jager P.L., Simon K.C., Munger K.L., Rioux J.D., Hafler D.A., and Ascherio A. Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 70 (2008) 1113-1118
142. Islam T., Gauderman W.J., Cozen W., Hamilton A.S., Burnett M.E., and Mack T.M. Differential twin concordance for multiple sclerosis by latitude of birthplace. Ann Neurol 60 (2006) 56-64
143. Haghighi S., Andersen O., Rosengren L., Bergstrom T., Wahlstrom J., and Nilsson S. Incidence of CSF abnormalities in siblings of multiple sclerosis patients and unrelated controls. J Neurol 247 (2000) 616-622
144. Celius E.G., Harbo H.F., Egeland T., Vartdal F., Vandvik B., and Spurkiand A. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci 178 (2000) 132-135
145. Hensiek A.E., Sawcer S.J., Feakes R., et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 72 (2002) 184-187
146. Sundstrom P., Nystrom L., Jidell E., and Hallmans G. EBNA-1 reactivity and HLA DRB1*1501 as statistically independent risk factors for multiple sclerosis: a case-control study. Mult Scler 14 (2008) 1120-1122
147. Nielsen T.R., Rostgaard K., Askling J., et al. Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis. Mult Scler 15 (2009) 431-436
148. De Jager P.L., Chibnik L.B., Cui J., et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol 8 (2009) 1111-1119
149. Kelly M.A., Cavan D.A., Penny M.A., et al. The influence of HLA-DR and -DQ alleles on progression to multiple sclerosis following a clinically isolated syndrome. Hum Immunol 37 (1993) 185-191
150. Hauser S.L., Oksenberg J.R., Lincoln R., et al. Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Neurology 54 (2000) 1859-1861